Smart Holdings dba Assurance Group Direct Announces Exclusive Deal to Sell Prescription and Generic Drugs Nationwide

MARIETTA, Ga.--(BUSINESS WIRE)-- Smart Holdings, Inc. (SMHS.PK), dba Assurance Group Direct announced today that the Company has signed a contract to sell all brand names and generic U.S. FDA approved prescription drugs nationwide through a National Drug Membership Card Program that can save consumers up to 70% or more. The membership includes the entire family for less than a $1 a day allowing consumers to buy direct from the same sources the big U.S. FDA approved pharmacies buy from. The membership will save consumers up to 40% discount at 98% off all U.S. walk-in pharmacies and even bigger savings up to 70% or more through home delivery where you can purchase up to a 90-day supply.

This program is different than all the free internet sites selling generic drugs without requiring a prescription. Our customers will need a prescription and can actually get the real prescribed brand name drugs or generic drugs filled by U.S. FDA approved pharmacies and delivered by mail. Companies on the internet selling drugs without requiring a prescription may not be considered safe, reliable or trustworthy.

Assurance Group will begin advertising the program on national TV the same way insurance is sold. Assurance Group anticipates building a membership base with recurring revenue. According to the provider, its 200,000 plus members have stayed members an average of 7 years and their dropout rate or membership cancelation rate is less than 1% a year proving the program is providing a quality service. The membership works like a co-pay insurance plan, except it is not insurance or a discount card.

This will be the first time this program has been marketed to the masses and the Company has an exclusive on national TV and internet marketing if the tests prove to be successful.

In addition, Assurance Group will be running a new TV campaign for its Extended Auto Warranty starting June 13th, testing a new product line. The Company remains positive about its future potential for growth.

About Smart Holdings, Inc.

Headquartered in Marietta, GA, Smart Holdings, Inc., through its wholly owned subsidiary, Assurance Group Direct, is in the business of selling automotive extended service plans on a nationwide basis directly to consumers through national television advertising and internet marketing, while continuing to add new product lines in the personal protection categories.

For more information, please visit: www.smartholdingsinc.com.

Forward Looking Statements

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Smart Holdings, Inc. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties.



CONTACT:

Smart Holdings, Inc.
Investor Relations
516-482-0155
[email protected]

KEYWORDS:   United States  North America  Georgia

INDUSTRY KEYWORDS:   Seniors  Women  Health  Pharmaceutical  Automotive  General Automotive  Consumer  Family  Men

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.